Cary Street Partners Asset Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-2,375
Closed -$914K 171
2021
Q3
$914K Sell
2,375
-2,873
-55% -$1.06M 0.32% 87
2021
Q2
$1.23M Sell
5,248
-18,328
-78% -$3.28M 0.29% 85
2021
Q1
$744K Buy
23,576
+4,176
+22% +$605K 0.18% 108
2020
Q4
$459K Buy
+19,400
New +$1.96M 0.14% 114

Other funds holding MRNA

Cary Street Partners Asset Management's MRNA Position: Q4 2021 in Review

Cary Street Partners Asset Management sold out of Moderna (MRNA) in Q4 2021, closing a stake of 2,375 shares — an estimated $914K sold.

Cary Street Partners Asset Management first reported a position in MRNA in Q4 2020 and held it in 4 quarters. The position peaked at $1.23M in Q2 2021. 1,110 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • Cary Street Partners Asset Management reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
  • Cary Street Partners Asset Management sold 2,375 Moderna shares in Q4 2021, an estimated $914K.
  • Cary Street Partners Asset Management first reported a position in Moderna in Q4 2020 and held it in 4 quarters.
  • Cary Street Partners Asset Management's Moderna position peaked at $1.23M in Q2 2021.
  • 1,110 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Cary Street Partners Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.